Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5806697 | 0.88 | HPGD (0.67) | MTNR1BRAB9AL3MBTL1GAAALOX15 | |
| SCHEMBL23080160 | 0.86 | MTNR1B (0.70) | MTNR1BRAB9AL3MBTL1GAAALOX15 | |
| SCHEMBL8278751 | 0.86 | MTNR1B (0.89) | MTNR1BRAB9AL3MBTL1GAAALOX15 | |
| SCHEMBL5142657 | 0.85 | NPC1 (0.75) | MTNR1BRAB9AL3MBTL1GAAALOX15 | |
| SCHEMBL4611370 | 0.85 | MTNR1B (0.72) | MTNR1BRAB9AL3MBTL1GAAALOX15 | |
| SCHEMBL3145750 | 0.85 | RAB9A (0.72) | MTNR1BRAB9AL3MBTL1GAAALOX15 | |
| SCHEMBL3145742 | 0.85 | RAB9A (0.72) | MTNR1BRAB9AL3MBTL1GAAALOX15 | |
| SCHEMBL13753200 | 0.84 | MTNR1B (0.75) | MTNR1BRAB9AL3MBTL1GAAALOX15 | |
| SCHEMBL1141400 | 0.83 | MTNR1B (0.81) | MTNR1BRAB9AL3MBTL1GAAALOX15 | |
| SCHEMBL2856692 | 0.83 | HPGD (0.68) | MTNR1BRAB9AL3MBTL1GAAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070281937-A1 | Ion Channel Modulators | SCION PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070203194-A1 | Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | SCION PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203194-A1 | Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | SCION PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| WO-2005087750-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281937-A1 | Ion Channel Modulators | CACNA1B, CACNA1C, TRPV1 | MTNR1B 616/4885RAB9A 1595/4885L3MBTL1 3558/4885 |
| US-20070203194-A1 | Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | CACNA1C, CACNA1D, CACNA1G | MTNR1B 423/4885RAB9A 2889/4885L3MBTL1 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.